Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720361 | 0.83 | POLB (0.49) | KCNH2CASP6RAB9ANPC1LMNA | |
| SCHEMBL3617512 | 0.83 | MCL1 (0.67) | KCNH2CASP6RAB9ANPC1TDP1 | |
| SCHEMBL23665874 | 0.82 | MCL1 (0.70) | KCNH2RAB9AKMT2ARXFP1KDM4E | |
| SCHEMBL718725 | 0.82 | RAB9A (0.54) | KCNH2RAB9ANPC1LMNAMAPT | |
| SCHEMBL30933195 | 0.82 | RAB9A (0.54) | KCNH2RAB9ANPC1LMNAMAPT | |
| SCHEMBL13787073 | 0.81 | CASP6 (0.62) | KCNH2CASP6RAB9ANPC1TDP1 | |
| SCHEMBL30790774 | 0.79 | TDP1 (0.64) | KCNH2CASP6RAB9ANPC1TDP1 | |
| SCHEMBL717905 | 0.79 | KCNH2 (0.67) | KCNH2CASP6RAB9ANPC1TDP1 | |
| SCHEMBL879305 | 0.78 | KCNH2 (0.59) | KCNH2RAB9ANPC1LMNAKMT2A | |
| SCHEMBL718514 | 0.77 | MCL1 (0.43) | KCNH2CASP6RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | KCNH2 2392/4885CASP6 831/4885RAB9A 2454/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | KCNH2 2392/4885CASP6 831/4885RAB9A 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.